The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications (Review)

Economidou,Foteini; Margaritopoulos,George; Antoniou,Katerina M.; Siafakas,Nikolaos M.

doi:10.3892/etm_00000001

The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications (Review)

Authors:
- Foteini Economidou
- George Margaritopoulos
- Katerina M. Antoniou
- Nikolaos M. Siafakas
View Affiliations

Affiliations: Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Greece
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000001
Pages: 3-7

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increased permeability of the pleural micro-vasculature is generally attributed to the substances that are released in inflammatory and malignant pleural effusions, although the exact pathogenetic mechanisms of malignant pleural effusions are unclear. Current therapies used to prevent the re-accumulation of pleural fluid and relieve symptoms are of variable efficacy and may cause serious adverse effects. Understanding the mechanisms of fluid accumulation would hopefully permit the development of more specific, effective and safer treatment modalities. Angiogenesis, pleural vascular increased permeability and inflammation are considered central to the pathogenesis of malignant pleural effusions. Vascular endothelial growth factor (VEGF) is a member of the VEGF/platelet-derived factor gene family and consists of at least six isoforms. Since it was shown that VEGF contributes to the formation of malignant pleural effusions, there have been some attempts to implicate, therapeutically, this finding using different molecules (ZD6474, PTK 787 and bevacizumab). However, the role of the biological axis of VEGF and angiopoietins needs further investigation in both the pathogenesis and the treatment of malignant pleural effusion. In both non-small-cell lung carcinoma and breast cancer, it has been shown that the ligand for CXCR4, CXCL12 or SDF-1α, exhibited peak levels of expression in organs that were the preferred destination for their respective metastases. Recent findings imply that new therapeutic strategies aimed at blocking the SDF-1-CXCR4 axis may have significant applications for patients by modulating the trafficking of hemato/lymphopoietic cells and inhibiting the metastatic behavior of tumor cells as well. The purpose of this report is to review novel pathogenetic and therapeutic implications regarding the angiogenetic pathways in malignant pleural effusions.

View Figures

View References

1.	Lee YC and Light RW: Management of malignant pleural effusions. Respirology. 9:148–156. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Antony VE, Loddenkepmper R, Astoul P, et al: Management of malignant pleural effusions. Am J Resp Crit Care Med. 162:1987–2001. 2000. View Article : Google Scholar
3.	West SD, Davies RJ and Lee YC: Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med. 10:305–310. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Kinasewitz GT: Transudative effusions. Eur Respir J. 10:714–718. 1997.PubMed/NCBI
5.	Light RW: Pleural diseases. Dis Mon. 38:261–331. 1992. View Article : Google Scholar
6.	Yanagama H, Takeuchi E, Suzuki Y, et al: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 48:396–400. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Lee YCG and Lane KB: Cytokines in pleural diseases. Textbook of Pleural Disease. Light RW and Lee YCG: Arnold; London: pp. 63–89. 2003
8.	Light RW: Talc for pleurodesis? Chest. 122:1506–1508. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Yano S, Shinohara H, Herbst RS, et al: Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 157:1893–1903. 2000. View Article : Google Scholar
10.	Stathopoulos GT, Zhu Z, Everhart MB, et al: Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol. 34:142–150. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Stathopoulos GT, Kollintza A, Moschos C, et al: Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res. 67:9825–9834. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Stathopoulos GT, Psallidas I, Moustaki A, et al: Tumor-derived monocyte chemoattractant protein-1 promotes malignant pleural effusion. J Natl Cancer Inst. 100:1464–1476. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Antony VB: Immunological mechanisms in pleural disease. Eur Respir J. 21:539–544. 2003. View Article : Google Scholar : PubMed/NCBI
14.	McDonald DM: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med. 164:S39–S45. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Hoshino M, Takahashi M and Aoike N: Expression of vascular endothelial growth factor, basic fibroblast growth factor and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 107:295–301. 2001. View Article : Google Scholar
16.	Hoshino M, Nakamura Y and Hamid QA: Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol. 107:1034–1038. 2000. View Article : Google Scholar : PubMed/NCBI
17.	Sack U, Hoffmann M, Zhao XJ, et al: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 25:600–604. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Ruiz E, Alemán C, Alegre J, et al: Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung. 183:185–195. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar
20.	Cheng D, Rodriguez RM, Perkett EA, et al: Vascular endothelial growth factor in pleural fluid. Chest. 116:760–765. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Grove CS and Lee YC: Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 8:294–301. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Yancopoulos GD, Davis S, Gale NW, et al: Vascular-specific growth factors and blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:439–442. 1996. View Article : Google Scholar : PubMed/NCBI
24.	Cheng D, Lee YC, Rogers JT, et al: Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions. Chest. 118:1747–1753. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Hamed EA, El-Noweihi AM, Mohamed AZ and Mahmoud A: Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology. 9:81–86. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Momi H, Matsuyama W, Inoue K, et al: Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med. 96:817–822. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Kalomenidis I, Kollintza A, Sigala I, et al: Angiopoietin-2 levels are elevated in exudative pleural effusions. Chest. 129:1259–1266. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Economidou F, Antoniou KM, Tzanakis N, et al: Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med. 102:774–779. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Duysinx BC, Corhay JL, Hubin L, et al: Diagnostic value of interleukin-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med. 102:1708–1714. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Carlomagno F, Vitagliano D, Guida T, et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:7284–7290. 2002.PubMed/NCBI
31.	Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 10:784–793. 2004. View Article : Google Scholar
32.	Frederick B, Gustafson D, Bianco C, et al: ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 64:33–37. 2006. View Article : Google Scholar : PubMed/NCBI
33.	Hennequin LF, Stokes ES, Thomas AP, et al: Novel 4-anilino-quinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem. 45:1300–1312. 2002. View Article : Google Scholar
34.	Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res. 62:4645–4655. 2002.PubMed/NCBI
35.	Williams KJ, Telfer BA, Brave S, et al: ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res. 10:8587–8593. 2004. View Article : Google Scholar
36.	Matsumori Y, Yano S, Goto H, et al: ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res. 16:15–26. 2006.
37.	Shibuya K, Komaki R, Shintani T, et al: Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 69:1534–1543. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Yano S, Herbst RS, Shinohara H, et al: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 6:957–965. 2000.PubMed/NCBI
39.	Wood JM, Bold G, Buchdunger E, et al: PTK 787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2178–2189. 2000.
40.	Li Q, Yano S, Ogino H, et al: The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 13:5918–5925. 2007. View Article : Google Scholar
41.	Thirkettle I, Harvey P, Hasleton PS, et al: Immunoreactivity for cadherins, HGF/SF, met and erbB-2 in pleural malignant mesotheliomas. Histopathology. 36:522–528. 2000. View Article : Google Scholar : PubMed/NCBI
42.	Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. Am J Pathol. 193:468–475. 2001. View Article : Google Scholar : PubMed/NCBI
43.	Dazzi H, Hasleton PS, Thatcher N, et al: Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4 monoclonal antibody. Br J Cancer. 61:924–926. 1990. View Article : Google Scholar
44.	Thaker PH, Deavers M, Celestino J, et al: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 10:5145–5150. 2004. View Article : Google Scholar : PubMed/NCBI
45.	Kinch MS, Moore MB and Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 9:613–618. 2003.PubMed/NCBI
46.	Easty DJ, Herlyn M and Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer. 60:129–136. 1995. View Article : Google Scholar : PubMed/NCBI
47.	Xu F, Zhong W, Li J, et al: Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res. 25:2943–2950. 2005.PubMed/NCBI
48.	Nasreen N, Mohammed KA and Antony VB: Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer. 107:2425–2435. 2006. View Article : Google Scholar : PubMed/NCBI
49.	Nasreen N, Mohammed KA, Lai Y and Antony VB: Receptor EphA2 activation with ephrin A1 suppresses growth of malignant mesothelioma (mm). Cancer Lett. 258:215–222. 2007. View Article : Google Scholar : PubMed/NCBI
50.	O’Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997.
51.	Nasreen N, Mohammed KA, Sanders K, et al: Pleural mesothelial cell (PMC) defense mechanisms against malignancy. Oncol Res. 14:155–161. 2003.PubMed/NCBI
52.	Nasreen N, Mohammed KA, Brown S, et al: Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J. 29:761–769. 2007. View Article : Google Scholar : PubMed/NCBI
53.	Bourguignon LY, Lokeshwar VB, Chen X and Kerrick WG: Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J Immunol. 151:6634–6644. 1993.PubMed/NCBI
54.	Nasreen N, Mohammed KA, Hardwick J, et al: Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res. 13:71–78. 2002.PubMed/NCBI
55.	Tsigos S, Koutsilieris M and Papapetropoulos A: Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs. 12:933–941. 2003. View Article : Google Scholar : PubMed/NCBI
56.	Thurston G, Rudge JS, Ioffe E, et al: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 6:460–463. 2006. View Article : Google Scholar : PubMed/NCBI
57.	Thurston G, Suri C, Smith K, et al: Leakage-resistant blood vessels in mice trangenically overexpressing angiopoietin-1. Science. 286:2511–2514. 1999. View Article : Google Scholar : PubMed/NCBI
58.	Kim I, Moon SO, Park SK, et al: Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1 and E-selectin expression. Circ Res. 89:477–479. 2001. View Article : Google Scholar : PubMed/NCBI
59.	Gamble JR, Drew J, Trezise L, et al: Angiopoietin-1 is an anti-permeability and anti-inflammatory agent in vitro and targets cell junctions. Cir Res. 87:603–607. 2000. View Article : Google Scholar : PubMed/NCBI
60.	Pizurki L, Zhou Z, Glynos K, et al: Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. J Pharmacol. 139:329–336. 2003.PubMed/NCBI
61.	Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
62.	Scharpfenecker M, Fiedler U, Reiss Y and Augustin HG: The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 118:771–780. 2005. View Article : Google Scholar : PubMed/NCBI
63.	Roviezzo F, Tsigkos S, Kotanidou A, et al: Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 314:738–744. 2005. View Article : Google Scholar : PubMed/NCBI
64.	Tanaka F, Yanagihara K, Otake Y, et al: Prognostic factors in resected pathologic (p-) stage IIIA-N2, non small cell lung cancer. Ann Surg Oncol. 11:612–618. 2004. View Article : Google Scholar : PubMed/NCBI
65.	Tomimoto H, Yano S, Muguruma H, et al: Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. J Med Invest. 54:146–153. 2007. View Article : Google Scholar : PubMed/NCBI
66.	Aiuti A, Tavian M, Cipponi A, et al: Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol. 29:1823–1831. 1999. View Article : Google Scholar : PubMed/NCBI
67.	Feng Y, Broder CC, Kennedy PE and Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane G, protein-coupled receptor. Science. 1272:872–877. 1996. View Article : Google Scholar
68.	Strieter RM, Belperio JA, Phillips RJ and Keane MP: CXC chemokines in angiogenesis of cancer. Semin Cancer Biol. 14:195–200. 2004. View Article : Google Scholar : PubMed/NCBI
69.	Phillips RJ, Burdick MD, Lutz M, et al: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
70.	Lee BC, Lee TH, Avraham S and Avraham HK: Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res. 2:327–338. 2004.
71.	Economidou F, Antoniou KM, Proklou A, et al: Investigation of angiogenetic mechanisms in pleural fluid of patients with lung cancer: preliminary results. Am J Respir Cell Mol Biol. 179:A28762009.
72.	Kucia M, Jankowski K, Reca R, et al: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI
73.	Oonakahara K, Matsuyama W, Higashimoto I, et al: Stromal-derived factor 1α/CXCL12-CXCR4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol. 30:671–677. 2004.